Use of Clonidine to Prevent Withdrawal Following Prolonged Dexmedetomidine Infusions
Information source: Nationwide Children's Hospital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Sedation
Intervention: Clonidine (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Joseph D. Tobias Official(s) and/or principal investigator(s):
Joseph D Tobias, MD, Principal Investigator, Affiliation: Nationwide Children's Hospital
Overall contact:
Julie Rice, RN, Phone: 6143553142, Email: julie.rice@nationwidechildrens.org
Summary
The investigators' clinical practice makes use of oral clonidine as a means of transitioning
from intravenous dexmedetomidine following prolonged infusions (more than 3-5 days).
Although this is common clinical practice, there is limited clinical data to demonstrate the
efficacy of this technique and to provide clonidine dosing guidelines. The purpose of this
study is to retrospectively review the investigators' experience with the use of oral
clonidine to prevent withdrawal following the prolonged administration of dexmedetomidine.
Clinical Details
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: Evidence of withdrawal
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients who received clonidine during the transition from dexmedetomidine.
Exclusion Criteria:
- None
Locations and Contacts
Julie Rice, RN, Phone: 6143553142, Email: julie.rice@nationwidechildrens.org Additional Information
Starting date: April 2015
Last updated: March 30, 2015
|
